Travere Therapeutics (TVTX) Earnings Date & Reports

Key Takeaways

• Travere Therapeutics (TVTX) is expected to report third quarter 2026 results in late October to early November, after the market close.
• Consensus estimates point to revenue of roughly $198 million, with earnings per share near breakeven — ranging from a small loss to a modest profit depending on the source.
• FILSPARI (sparsentan), the company's lead rare kidney disease drug, remains the core growth driver across its IgA nephropathy (IgAN) and newly launched focal segmental glomerulosclerosis (FSGS) indications.
• Last quarter, TVTX beat revenue expectations but missed on earnings per share; shares still rallied on record FILSPARI demand and a strong FSGS launch.
• Investors will watch patient start forms, gross-to-net pricing dynamics, and progress on the Phase III HARMONY study of pegtibatinase.

Earnings Context and Why It Matters

Travere Therapeutics is a biopharmaceutical company focused on rare kidney and metabolic diseases, and its growth story now revolves almost entirely around FILSPARI. The drug is approved for IgA nephropathy (a chronic kidney condition) and, more recently, for FSGS — a launch that began generating revenue almost immediately. That commercial momentum makes each quarterly print a key signal for investors. In the second quarter of 2026, the company reported total revenue of about $169.6 million, beating consensus, with FILSPARI sales surging roughly 96% year over year. The upcoming third quarter report will test whether that demand is sustainable and whether the FSGS launch continues to scale ahead of expectations.

Earnings Expectations

For the third quarter of 2026, Wall Street expects Travere Therapeutics to report revenue of approximately $198 million, according to consensus estimates. On the bottom line, forecasts are clustered near breakeven, with analysts projecting results ranging from a small loss to a modest profit per share — reflecting the company's transition toward profitability as FILSPARI sales expand.

Revenue growth will again be driven primarily by FILSPARI net product sales. In the second quarter, FILSPARI generated about $141.1 million in U.S. sales on record demand, with more than 2,000 new patient start forms across IgA nephropathy and FSGS. Management has also flagged that gross-to-net discounts are expected to remain in the mid-20% range for 2026, a metric investors should watch closely for any impact on realized pricing.

Beyond the headline numbers, the market will focus on FSGS launch trajectory, patient start form counts, and any updates to full-year guidance. Historically, TVTX shares have reacted sharply to demand-related news rather than bottom-line beats alone, making the commercial metrics at least as important as the earnings per share figure.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable filters that include industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking earnings season, it can help surface stocks with notable technical setups ahead of or following major reports. Explore the AI Screener to refine your own market watchlist.

Market Reaction and Investor Sentiment

Sentiment heading into the third quarter report is broadly constructive. Following the second quarter release in August 2026, shares rose sharply as investors rewarded record FILSPARI demand and the early strength of the FSGS launch, even though earnings per share came in below consensus. That reaction underscores a key dynamic: the market is primarily valuing TVTX on its commercial growth trajectory rather than near-term profitability.

Still, risks remain. The stock has been volatile around earnings in the past, and any sign of slowing patient starts, softer-than-expected FSGS uptake, or heavier gross-to-net discounts could weigh on sentiment. Conversely, continued demand momentum and a reaffirmed peak sales target for FILSPARI could support further optimism.

Forward Outlook and Key Factors to Monitor

Looking beyond the third quarter, the central question is whether FILSPARI can sustain its dual-indication growth. In IgA nephropathy, the company continues to expand prescribing depth while navigating an increasingly competitive treatment landscape. In FSGS, early launch metrics have outpaced the initial IgA nephropathy rollout, but management has cautioned that a single quarter is not enough to extrapolate long-term trends.

Investors should also monitor the broader pipeline. The Phase III HARMONY study of pegtibatinase, a potential disease-modifying therapy for classical homocystinuria (HCU), is actively enrolling, with results anticipated in the second half of 2027. Additionally, the company recently expanded its rare kidney disease portfolio through an exclusive licensing agreement for civorebrutinib, adding an upstream immune-modulating approach with potential across multiple immune-mediated kidney diseases.

On the financial side, watch for updates on cash position, operating expense trends, and any commentary on the company's recent convertible notes refinancing. Research and development spending may remain elevated as the HARMONY study progresses, while selling, general, and administrative costs reflect the expanded commercial field team supporting the FSGS launch. These factors will shape the path toward sustained profitability.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations